Welcome to our open bookshelf on the future of longevity. Our vision is to make aging and age-related diseases optional for all. 

age1 funds breakthrough longevity companies addressing the core challenges of the field. We help contrarian founders build generational biotech companies. 

Our expertise is at the earliest stage possible. We are a next-generation fund accelerating the longevity paradigm shift. We value pragmatism, rigor, and optimism. Launched from The Longevity Fund, we’ve backed some of the first longevity biotech companies to IPO and achieve clinical translation. 

If you’re building in this space, reach out via our website or info[at]age1.com. 

Subscribe to Libraries for the Future

Deep dives into the future of longevity


Early backer of breakthrough, founder-led longevity companies